UNSPSC 51284026: Doxycycline fosfatex

This classification denotes a tetracycline antibiotic with the molecular formula 3C22H24N2O8.Na.O3P.3HO3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2IQ26U2DZQ, chemically known as (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide, compound with sodium trihydrogen metaphosphate (h(sub 3)nap(sub 4)o(sub 12)) (3:1), but more generally known as doxycycline fosfatex, which bears US NIH Compound Identifier 6441613.

UNSPSC 51284026 Doxycycline fosfatex is a Commodity code that appears in state and local procurement records with little recent relevance to its nominal scope. The recent opportunities tagged to this code—naloxone and drug deactivation systems procurement, therapeutic pharmacy initiative direct-to-manufacturer contracts, emergency medical and first aid supplies, and generic multi-source pharmaceutical cooperative purchasing—do not align with doxycycline fosfatex, a specific tetracycline antibiotic formulation. The mismatch suggests either miscoding in the source records or a disconnect between the UNSPSC taxonomy and how issuing bodies classify pharmaceutical procurements in practice.

The handful of recent opportunities that do surface under or near this code involve health and human services agencies, cities, and multistate cooperative purchasing alliances buying a broad range of pharmaceutical products, medical supplies, and drug-control systems rather than a single active pharmaceutical ingredient. Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems through competitive bidding; the City of Tampa (Bid 26P00145, due March 13, 2026) solicited medical and first aid supplies for its fire rescue division with an estimated contract value of $700,000 and a 5 percent small local business enterprise discount; the Texas Health and Human Services Commission (RFI HHS0017013, issued April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) established contracts for generic multi-source pharmaceuticals and over-the-counter products across participating states and local governments. The code shows limited decision-relevant activity under its stated name and warrants confirmation of actual commodity alignment before pursuit.